Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study.

Christopher L Bowlus,Bertus Eksteen,Angela C Cheung,Douglas Thorburn,Cynthia A Moylan,Paul J Pockros,Lisa M Forman,Alejandro Dorenbaum,Gideon M Hirschfield,Ciara Kennedy, Thomas Jaecklin,Andrew McKibben,Elaine Chien,Marshall Baek,Pamela Vig,Cynthia Levy

Hepatology communications（2023）

引用 1|浏览17

暂无评分

摘要

Maralixibat was associated with reduced sBA levels in adults with PSC. In participants with more severe baseline pruritus, pruritus improved significantly from baseline. TEAEs were mostly gastrointestinal related. These results support further investigation of IBAT inhibitors for adults with PSC-associated pruritus. ClinicalTrials.gov: NCT02061540.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要